ArticleJTO clinical and research reports2023

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced

Qing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.